Berkadia Medical & Life Sciences
Fall 2025 U.S. Medical & Life Sciences Report
Medical and life sciences investors and developers continued to curb transaction activity in the first half of 2025 as they held out for the promise of reduced interest rates. Additionally, increased construction costs slowed medical outpatient building development, resulting in continued growth in occupancy and rental rates. For life sciences, oversupply combined with decreased demand due to muted public and private funding has pushed occupancy to record lows, even with slowed development. Transaction activity for medical outpatient buildings has picked up in Q4, however, due to interest rate relief and pent-up demand following a sluggish start to the year.
CONTACT US
HEAD OF MEDICAL & LIFE SCIENCES
SABRINA SOLOMIANY
Senior Managing Director
404.536.5054
Email me
CHRIS LASHMET
Managing Director
847.209.0425
Email me
ERIC LEE
Managing Director
763.226.8563
Email me
VASILI DAVOS
Senior Director
214.360.3858
Email me
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
